PIA
INSY

Piedmont Investment Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

Piedmont Investment Advisors’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-467
Closed -$3K – 2826
2018
Q2 		$3K Buy
+467
New +$3.26K ﹤0.01% 2506
2017
Q1 		– Sell
-127
Closed -$1.17K – 684
2016
Q4 		$1.17K Hold
127
– – ﹤0.01% 656
2016
Q3 		$1.5K Buy
127
+113
+807% +$1.72K ﹤0.01% 428
2016
Q2 		$181 Sell
14
-46
-77% -$670 ﹤0.01% 572
2016
Q1 		$959 Buy
60
+17
+40% +$323 ﹤0.01% 376
2015
Q4 		$1.23K Buy
+43
New +$1.19K ﹤0.01% 376

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Piedmont Investment Advisors's INSY Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q3 2018, closing a stake of 467 shares — an estimated $3K sold.

Piedmont Investment Advisors first reported a position in INSY in Q4 2015 and held it in 6 quarters. The position peaked at $3K in Q2 2018. 110 funds tracked by Wall St. Rank hold INSY as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Insys Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 467 Insys Therapeutics, Inc. shares in Q3 2018, an estimated $3K.
  • Piedmont Investment Advisors first reported a position in Insys Therapeutics, Inc. in Q4 2015 and held it in 6 quarters.
  • Piedmont Investment Advisors's Insys Therapeutics, Inc. position peaked at $3K in Q2 2018.
  • 110 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.